Clinical trial · Interventional
Effect of Intravenous Magnesium on Postoperative Systemic Inflammatory Response in Patients Undergoing Colorectal Cancer Surgery
NCT07803601CI-TRIAL-00125748recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to detect the effect of intraoperative intravenous magnesium sulfate on postoperative systemic inflammatory response by serum inflammatory parameters as CRP, WBCS and neutrophil count.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Post Operative Inflammatory Marker Levels | — | UNRESOLVED | — |
| Post Operative Pain | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnesium sulfate (MgSO4) | Drug | — | UNRESOLVED |
| Normal Saline | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- study group (magnesium sulfate group)
- description
- After the induction of anesthesia, the patients will receive loading intravenous magnesium sulfate (50mg/kg over 20 minutes) and maintenance (15mg/kg/hr) till the end of surgery.
- interventionNames
- Drug: Magnesium sulfate (MgSO4)
- type
- PLACEBO_COMPARATOR
- label
- control group
- description
- The patients will receive the same normal saline volume for loading and maintenance.
- interventionNames
- Drug: Normal Saline
Primary outcomes (1)
- measure
- postoperative white blood cell count (WBC)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 35 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * ASA I and ASA II. * Age (35yrs - 75yrs). * Patients undergoing open colorectal cancer surgery. * Sex: Both sexes. Exclusion Criteria: * Renal impairment (Glomerular Filtration Rate \< 60 ml\\min). * Severe cardiac dysfunction (Ejection fraction ≤ 30% or clinical signs and symptoms of reduced left ventricular ejection fraction), preoperative bradycardia (HR \< 50 bpm) and atrioventricular block (first, second and third degree). * Allergy to study drug (MgSO4). * Patient refusal to precipitate in this study. * Autoimmune disorders (eg: rheumatoid arthritis, multiple sclerosis and lupus), congenital and acquired immunodeficiency. * Previous / current immunomodulatory therapy. * Emergency condition (eg: obstruction or perforation in colorectal cancer). * Postoperative complications altering inflammatory response (eg: infection, anastomotic leak). * Duration of operation \> 5 hours. * Cognitive impairment (eg: Dementia) and other psychiatric disorders by history. * Body mass index less than 18 or greater than 30 kg/m².
References
Publications (0)
Data not yet available
No reference posted for this study.